Pharmacists; collaborative agreements, drug therapy.

Document layout changed from House bill format to Senate substitute format with new header information and line numbers.

Date placeholder changed from February 13, 2025 to blank line for Senate committee date entry.

Added Senate substitute identification numbers and tracking codes not present in original House version.

Document format changed from Enrolled Act to Substitute Amendment with updated header information including Senate Committee attribution and draft status

Added new provisions allowing pharmacists to prescribe, modify, continue, or discontinue Schedule II through VI controlled substances under collaborative agreements.

Added requirement that pharmacists must submit proof of signed collaborative practice agreements to the Board and obtain authorization before prescribing controlled substances.

Modified Section E to clarify that nothing in the section supersedes existing provisions while adding new controlled substance prescribing authority.

Added specific examples of prescriber types (licensed physician, podiatrist, advance practice registered nurse, registered nurse, or physician assistant) in subsection C to clarify who can participate in collaborative agreements for drug therapy protocols.

Updated bill header information to reflect engrossed status with House amendments dated January 21, 2025, and changed session status from 'Introduced' to 'Engrossed'.

Added line breaks and spacing adjustments throughout the document for proper legislative formatting.